![](/images/graphics-bg.png)
Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma
Joint Authors
Leguerney, Ingrid
de Rochefort, Ludovic
Poirier-Quinot, Marie
Ingels, Alexandre
Violas, Xavier
Robin, Sandra
Opolon, Paule
Dubuisson, Rose-Marie
Pitre-Champagnat, Stéphanie
Robert, Philippe
Lassau, Nathalie
Source
Contrast Media & Molecular Imaging
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-04-09
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Molecular magnetic resonance imaging targeted to an endothelial integrin involved in neoangiogenesis was compared to DCE-US and immunochemistry to assess the early response of three different therapeutic agents in renal cell carcinoma.
Human A498 renal cells carcinoma was subcutaneously inoculated into 24 nude mice.
Mice received either phosphate-buffered saline solution, sunitinib, everolimus, or bevacizumab during 4 days.
DCE-US and molecular MRI targeting αvβ3 were performed at baseline and 4 days after treatment initiation.
PI, AUC, relaxation rate variations ΔR2⁎, and percentage of vessels area quantified on CD31-stained microvessels were compared.
Significant decreases were observed for PI and AUC parameters measured by DCE-US for bevacizumab group as early as 4 days, whereas molecular αvβ3-targeted MRI was able to detect significant changes in both bevacizumab and everolimus groups.
Percentage of CD31-stained microvessels was significantly correlated with DCE-US parameters, PI (R=0.87, p=0.0003) and AUC (R=0.81, p=0.0013).
The percentage of vessel tissue area was significantly reduced (p<0.01) in both sunitinib and bevacizumab groups.
We report an early detection of neoangiogenesis modification after induction of targeted therapies, using DCE-US or αvβ3-targeted MRI.
We consider these outcomes should encourage clinical trial developments to further evaluate the potential of this molecular MRI technique.
American Psychological Association (APA)
Leguerney, Ingrid& de Rochefort, Ludovic& Poirier-Quinot, Marie& Ingels, Alexandre& Violas, Xavier& Robin, Sandra…[et al.]. 2017. Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma. Contrast Media & Molecular Imaging،Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1141842
Modern Language Association (MLA)
Leguerney, Ingrid…[et al.]. Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma. Contrast Media & Molecular Imaging No. 2017 (2017), pp.1-8.
https://search.emarefa.net/detail/BIM-1141842
American Medical Association (AMA)
Leguerney, Ingrid& de Rochefort, Ludovic& Poirier-Quinot, Marie& Ingels, Alexandre& Violas, Xavier& Robin, Sandra…[et al.]. Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma. Contrast Media & Molecular Imaging. 2017. Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1141842
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141842